癌症拦截（CI）是一种新型的癌症预防和治疗方法，旨在在患有癌症风险的人群中检测和治疗癌前阶段。它与传统的癌症诊断和监测方法相比具有几个潜在优势，因为它是非侵入性的，相对于传统的活检过程，不仅更少痛苦，而且风险较低。循环肿瘤细胞（CTCs）作为液体活检成员对CI方法至关重要；因此，液体活检（LB）被用作CI工具。由于易采样和早期病理阶段，LB可以频繁进行，从而允许对癌症进展和治疗反应进行重复的非侵入性监测。CTCs已在多种癌症患者的血液中发现，包括早期癌症和癌前病变，这表明它们在癌症早期阶段的肿瘤发展中发挥重要作用。本章将介绍关于CI的基础科学研究以及CTC筛查在癌症高风险人群中的临床影响。版权所有 © 2023 Elsevier Inc. 发表。

Cancer interception (CI) is a new approach to cancer prevention and treatment in a cancer-risk population that aims to detect and treat pre-tumoral stages. It has several potential advantages over traditional cancer diagnosis and monitoring methods because it is non-invasive, making it less painful and risky than conventional biopsy procedures. The circulating tumor cells (CTCs), liquid biopsy family members, are essential for the CI approach; then, the liquid biopsy (LB) is used as a CI tool. LB can be performed frequently because of its easy sampling and early pathological stages, which allow repeated non-invasive monitoring of cancer progression and response to treatment. CTCs have been found in the bloodstream of several types of cancer patients, including in early-stage cancer and premalignant lesions, suggesting a tumor development role in cancer's early stages. This chapter will present foundational scientific studies addressing CI and the clinical impact of CTC screening in a population at risk for cancer.Copyright © 2023. Published by Elsevier Inc.